Diabetes drug inhibits post-meal drop in BP

Key points
- The anti-diabetes drug voglibose can help reduce a drop in blood pressure after eating, so-called postprandial hypotension, Japanese researchers report.
- Reduced blood pressure after a meal is common in the elderly and in those with conditions such as Parkinson's disease and diabetes mellitus.
- To examine the effect of voglibose on postprandial hypotension, Dr.
- Following voglibose administration, there was a significant reduction in this drop in blood pressure.
The anti-diabetes drug voglibose can help reduce a drop in blood pressure after eating, so-called postprandial hypotension, Japanese researchers report.
Reduced blood pressure after a meal is common in the elderly and in those with conditions such as Parkinson's disease and diabetes mellitus. It can increase the risk of falls and coronary events.
To examine the effect of voglibose on postprandial hypotension, Dr. Takahiro Maruta of Kanazawa University and colleagues studied 48 elderly subjects, including those with Parkinson's disease, multiple system atrophy and diabetes as well as elderly and younger controls without these disorders.
They report in the journal Neurology that within 2 hours of "glucose loading," blood pressure fell by more than 20 millimeters mercury in roughly 73 percent of the Parkinson's patients, all of those with multiple system atrophy, 27 percent of the patients with diabetes, 23 percent of the elderly controls and none of the younger controls.
Following voglibose administration, there was a significant reduction in this drop in blood pressure. Without voglibose, the mean drop was 41.5 millimeters mercury; with voglibose, it was 21.0 mm Hg.
There was also a reduction in the duration of after-meal hypotension under the two conditions (52 minutes versus 17 minutes).
Summing up, Maruta told Reuters Health, "Many people suffer from symptoms due to (low blood pressure). Our research should cast some light on ways to help them."
SOURCE: Neurology May 9, 2006.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Heart & Blood Vessels →
NewsFDA OKs Drug for Rare Lipid Disorder
The FDA has approved the lipid-lowering drug lomitapide (Juxtapid) as add-on therapy in patients with a rare lipid disorder , the agency announced Wednesday. The drug is for homozygous familial hypercholesterolemia…
30 December 2012
NewsKentucky study finds common drug increases deaths in atrial fibrillation patients
Digoxin, a drug widely used to treat heart disease, increases the possibility of death when used by patients with a common heart rhythm problem − atrial fibrillation (AF), according to new study findings by University…
28 November 2012
NewsNovartis heart failure drug cuts death by 37 percent: study
An experimental Novartis AG drug to treat hospitalized acute heart failure patients reduced deaths by 37 percent compared with a placebo and appeared to be safe, according to data from a late stage clinical trial…





